Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation
暂无分享,去创建一个
A. Cohen-Solal | L. Lund | P. McEwan | D. Pascual-Figal | S. Haehling | J. Comín-Colet | F. Dorigotti | M. Ohlsson | Ruth D. Lewis | E. Jankowska | P. Ponikowski | Lars H. Lund | Ewa A. Jankowska | Cale Harrison | Rhona Binnie | Ruth D. Lewis | Stephan Haehling | Domingo A. Pascual‐Figal | Sandra Wächter | Antonio Ramirez Arellano | Antonio Ramirez Arellano
[1] E. Vinyoles,et al. Burden of heart failure in primary healthcare , 2022, Atencion primaria.
[2] P. Ponikowski,et al. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF , 2021, European journal of heart failure.
[3] N. Bragazzi,et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. , 2021, European journal of preventive cardiology.
[4] P. Ponikowski,et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study , 2011, European heart journal.
[5] P. Ponikowski,et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial , 2020, The Lancet.
[6] J. Delgado,et al. Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain , 2020, Journal of medical economics.
[7] R. Wachter,et al. Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials , 2020, European journal of heart failure.
[8] P. Ponikowski,et al. Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction , 2020, European journal of heart failure.
[9] A. Székely,et al. Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania , 2019 .
[10] P. Ponikowski,et al. Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐deficient patients admitted for acute heart failure , 2019, European journal of heart failure.
[11] S. Gerzeli,et al. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact. , 2019, Journal of comparative effectiveness research.
[12] A. Cohen-Solal,et al. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France , 2019, ESC heart failure.
[13] C. Linde,et al. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries , 2018, Scandinavian cardiovascular journal : SCJ.
[14] K. Claxton,et al. Discounting in Economic Evaluations , 2018, PharmacoEconomics.
[15] Peter Kolominsky-Rabas,et al. Cost-of-illness studies in heart failure: a systematic review 2004–2016 , 2018, BMC Cardiovascular Disorders.
[16] W. Doehner,et al. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany , 2017, ESC heart failure.
[17] A. Voors,et al. Comorbidities in Heart Failure. , 2017, Handbook of experimental pharmacology.
[18] Gianluigi Savarese,et al. Global Public Health Burden of Heart Failure. , 2016, Cardiac failure review.
[19] E. Walter,et al. Cost-Effectiveness Of Ferric Carboxymaltose In Patients With Iron Deficiency And Chronic Heart Failure In Austria. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[20] P. Ponikowski,et al. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. , 2015, Revista espanola de cardiologia.
[21] A. Cohen-Solal,et al. Iron deficiency: an emerging therapeutic target in heart failure , 2014, Heart.
[22] P. Ponikowski,et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. , 2014, International journal of cardiology.
[23] P. Ponikowski,et al. Iron deficiency in chronic heart failure: an international pooled analysis. , 2013, American heart journal.
[24] P. Ponikowski,et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives , 2012, European heart journal.
[25] P. Ponikowski,et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK , 2012, European journal of heart failure.
[26] Alan D. Lopez,et al. The Global Burden of Disease Study , 2003 .